Recently, Wu et al. [53] showed that a trispecific antibody (Figure 2) directed against CD38, CD3, and CD28, which is a recognized T cells co-stimulatory protein, had a killing capacity in CD38+ myeloma cell lines 3–4 log higher than daratumumab. This evidence concerns the gene CD38 and plasma cell myeloma.